What is HC Wainwright’s Forecast for LSTA FY2024 Earnings?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Lisata Therapeutics in a note issued to investors on Thursday, November 21st. HC Wainwright analyst J. Pantginis now expects that the company will earn ($2.64) per share for the year, up from their previous estimate of ($2.99). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q4 2024 earnings at ($0.79) EPS, FY2025 earnings at ($1.83) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.26) EPS.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same period in the prior year, the firm earned ($0.65) earnings per share.

Lisata Therapeutics Trading Down 1.4 %

LSTA opened at $2.84 on Monday. Lisata Therapeutics has a 1-year low of $2.05 and a 1-year high of $3.83. The stock has a market capitalization of $23.83 million, a price-to-earnings ratio of -1.13 and a beta of 1.22. The business has a 50 day moving average of $2.93 and a 200-day moving average of $3.09.

Institutional Investors Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.